Search results

Page title matches

• Rofecoxib
  ...eicin A, ''et al'' |title=Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group |jour
  2 KB (331 words) - 10:20, 25 May 2010
• Rofecoxib/Approval
  12 bytes (1 word) - 20:41, 21 December 2007
• Rofecoxib/Definition
  183 bytes (21 words) - 10:55, 8 September 2009
• Rofecoxib/Related Articles
  Auto-populated based on [[Special:WhatLinksHere/Rofecoxib]]. Needs checking by a human.
  533 bytes (66 words) - 20:05, 11 January 2010

Page text matches

• Rofecoxib
  ...eicin A, ''et al'' |title=Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group |jour
  2 KB (331 words) - 10:20, 25 May 2010
• Rofecoxib/Related Articles
  Auto-populated based on [[Special:WhatLinksHere/Rofecoxib]]. Needs checking by a human.
  533 bytes (66 words) - 20:05, 11 January 2010
• Cyclooxygenase 2 inhibitor/Related Articles
  {{r|Rofecoxib}}
  655 bytes (80 words) - 15:48, 11 January 2010
• Cyclooxygenase 2 inhibitor
  [[Rofecoxib]] was voluntarily withdrawn from the market by Merck & Co in September, 200
  2 KB (265 words) - 09:16, 28 December 2010
• Scientific journal
  ...publications related to rofecoxib: a case study of industry documents from rofecoxib litigation |journal=JAMA |volume=299 |issue=15 |pages=1800–12 |year=2008 | [[Rofecoxib]]|| Merck||•  "Seeding trial" - conducting and publishing a [[ran
  32 KB (4,430 words) - 08:23, 27 September 2012
• Conflict of interest
  ...Furberg CD, Avorn J| title=Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. | journal=Am Heart J | year= 2012 | volume= 164
  25 KB (3,499 words) - 11:45, 2 February 2023
• Primary care physician
  ...l |author=Rawson N ''et al.'' |title=Factors associated with celecoxib and rofecoxib utilization |journal=Ann Pharmacother |volume=39 |pages=597-602 |year=2005
  25 KB (3,536 words) - 05:23, 25 November 2020
• Food and Drug Administration
  ...igan D, Hill KP, Egilman DS, Wang Y, Krumholz HM| title=Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutic After concerns of slow approvals, the In 2004, the [[rofecoxib|Vioxx]] controversy revealed that the FDA had instances of insufficient ove
  40 KB (5,751 words) - 04:07, 19 September 2013
• Evidence-based medicine/Citable Version
  ...l |author=Rawson N ''et al.'' |title=Factors associated with celecoxib and rofecoxib utilization |journal=Ann Pharmacother |volume=39 |pages=597-602 |year=2005
  55 KB (7,444 words) - 06:21, 29 August 2013
• Evidence-based medicine/Bibliography
  ...l |author=Rawson N ''et al.'' |title=Factors associated with celecoxib and rofecoxib utilization |journal=Ann Pharmacother |volume=39 |pages=597-602 |year=2005
  27 KB (3,605 words) - 11:27, 2 December 2013
• Randomized controlled trial
  ...Furberg CD, Avorn J| title=Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. | journal=Am Heart J | year= 2012 | volume= 164
  87 KB (12,105 words) - 14:08, 2 February 2023
• Evidence-based medicine
  ...l |author=Rawson N ''et al.'' |title=Factors associated with celecoxib and rofecoxib utilization |journal=Ann Pharmacother |volume=39 |pages=597-602 |year=2005
  63 KB (8,790 words) - 06:57, 2 March 2021